{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:02:06Z","timestamp":1794502926948,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41591-025-03937-8","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:16:56Z","timestamp":1758705416000},"page":"3725-3736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Jingjing","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5402-5623","authenticated-orcid":false,"given":"Xuexiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-309X","authenticated-orcid":false,"given":"Alex Hongsheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-0726","authenticated-orcid":false,"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-4115","authenticated-orcid":false,"given":"Linrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-9380","authenticated-orcid":false,"given":"Jin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-1852","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"3937_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: a review. JAMA 331, 1480\u20131491 (2024).","journal-title":"JAMA"},{"key":"3937_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736\u2013745 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"3937_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3937_CR4","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"3937_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3937_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev. Rep. 17, 2120\u20132123 (2021).","journal-title":"Stem Cell Rev. Rep."},{"key":"3937_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 83, 1304\u20131314 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"3937_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46053-w","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen, W. et al. Distinct transcriptomes and autocrine cytokines underpin maturation and survival of antibody-secreting cells in systemic lupus erythematosus. Nat. Commun. 15, 1899 (2024).","journal-title":"Nat. Commun."},{"key":"3937_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13075-015-0551-3","volume":"17","author":"A Taddeo","year":"2015","unstructured":"Taddeo, A. et al. Long-lived plasma cells are early and constantly generated in New Zealand Black\/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res. Ther. 17, 39 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"3937_CR10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1084\/jem.20040168","volume":"199","author":"BF Hoyer","year":"2004","unstructured":"Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice. J. Exp. Med. 199, 1577\u20131584 (2004).","journal-title":"J. Exp. Med."},{"key":"3937_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/ard.2008.096495","volume":"69","author":"AM Jacobi","year":"2010","unstructured":"Jacobi, A. M. et al. HLA-DRhigh\/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 305\u2013308 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"3937_CR12","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50, 3580\u20133590 (2004).","journal-title":"Arthritis Rheum."},{"key":"3937_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","volume":"43","author":"JL Halliley","year":"2015","unstructured":"Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow. Immunity 43, 132\u2013145 (2015).","journal-title":"Immunity"},{"key":"3937_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj9730","volume":"9","author":"C Qin","year":"2024","unstructured":"Qin, C. et al. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity. Sci. Immunol. 9, eadj9730 (2024).","journal-title":"Sci. Immunol."},{"key":"3937_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","volume":"82","author":"MK Crow","year":"2023","unstructured":"Crow, M. K. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann. Rheum. Dis. 82, 999\u20131014 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"3937_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103477","volume":"70","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine 70, 103477 (2021).","journal-title":"EBioMedicine"},{"key":"3937_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485 (2011).","journal-title":"Nature"},{"key":"3937_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent, F. B., Morand, E. F., Schneider, P. & Mackay, F. The BAFF\/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 10, 365\u2013373 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"3937_CR19","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 6, e521\u2013e529 (2019).","journal-title":"Lancet Haematol."},{"key":"3937_CR20","doi-asserted-by":"crossref","unstructured":"Yang, C. et al. Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus. Cell Res. 35, 607\u2013609 (2025).","DOI":"10.1038\/s41422-025-01128-1"},{"key":"3937_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103229","volume":"83","author":"J Shu","year":"2025","unstructured":"Shu, J. et al. Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. EClinicalMedicine 83, 103229 (2025).","journal-title":"EClinicalMedicine"},{"key":"3937_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09489-1","volume":"22","author":"L An","year":"2022","unstructured":"An, L. et al. Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer 22, 393 (2022).","journal-title":"BMC Cancer"},{"key":"3937_CR23","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin. Cancer Res. 27, 6384\u20136392 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3937_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005701","volume":"11","author":"F Song","year":"2023","unstructured":"Song, F. et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J. Immunother. Cancer 11, e005701 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"3937_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03937-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03937-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03937-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:13:17Z","timestamp":1763140397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03937-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3937"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03937-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.H.C. is a founding member of Shanghai YaKe Biotechnology, Ltd., a biotechnology company focusing on research and development of tumor cellular immunotherapy. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}